<DOC>
	<DOCNO>NCT02888301</DOCNO>
	<brief_summary>This clinical trial study 18F-clofarabine positron emission tomography ( PET ) /computed tomography ( CT ) image patient cancer treatment therapy activate patient 's immune system ( immunotherapy ) . PET/CT scan give detailed picture area inside body . 18F-clofarabine drug contains radioactive substance take cell express deoxycytidine kinase ( dCK ) , highly express activate immune cell , make light PET/CT scan . Doctors also want know 18F-clofarabine distribute throughout body treatment immunotherapy .</brief_summary>
	<brief_title>18F-Clofarabine PET/CT Imaging Cancer Patients Before After Interventions</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether positron emission tomography ( PET ) use new image agent 18F-clofarabine use imaging cancer , whether intervention activate immune system change biodistribution 18F-clofarabine . OUTLINE : Patients receive 18F-clofarabine intravenously ( IV ) undergo PET/CT scan baseline 2-4 week completion immunotherapy .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Must able tolerate PET/CT ( i.e . claustrophobic able remain supine ) No restriction base gender racial/ethnic background Women childbearing age undergo pregnancy test provide free charge</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>